This article was downloaded by:


On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis of Alkylating 1-Glycosyl-5-substituted 1,2,4-Triazoles¹

Federico G. De las Heras^a; María-José Camarasa^a Instituto de Quïmica Médica, Madrid, Spain

To cite this Article Heras, Federico G. De las and Camarasa, María-José(1982) 'Synthesis of Alkylating 1-Glycosyl-5-substituted 1,2,4-Triazoles'', Nucleosides, Nucleotides and Nucleic Acids, 1: 1, 45 — 56

To link to this Article: DOI: 10.1080/07328318208079401 URL: http://dx.doi.org/10.1080/07328318208079401

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF ALKYLATING 1-GLYCOSYL-5-SUBSTITUTED 1,2,4-TRIAZOLES¹

Federico G. De las Heras and María-José Camarasa.

Instituto de Química Médica. Juan de la Cierva 3. Madrid 6. Spain

Abstract. A series of alkylating derivatives of 5-substituted 1-glycosyl-1,2,4-triazole having cytostatic activity has been prepared. The compounds synthesized include the 5-hydroxymethyl, 5-halomethyl, 5-(1-aziridino) methyl, and 5-bis (2-chloroethyl) aminomethyl derivatives.

In previous papers in this series the synthesis, cytostatic activity and mechanism of action of halomethyl 1,2,3-triazole $\underline{1}^2$,3,4 pyrazole $\underline{2}^5$, and imidazole $\underline{3}^6$ alkylating N-glycosides was reported. The significant "in vivo" cytostatic activities of 4-bromo- and 4-iodomethyl-1-peracetyl glycosyl-1,2,3-triazoles $\underline{1}$ against Ehrlich carcinoma ascites tumor 2 ,3 and P-388 Lymphocytic leukemia prompted us to extend our studies to the biologically important 7 ,8 1,2,4-triazole series. In this paper we describe the synthesis of a series of triacetyl- β -D-ribofuranosyl and tetraacetyl- β -D-glucopyranosyl derivatives of 1,2,4-triazole substituted at the 5-position with halomethyl, nitrogen mustard and aziridine alkylating groups.

The synthetic route started with the preparation of peracety1- β -D-glycosy1-1,2,4-triazoles $\underline{4}^8$. Fusion of 1,2,3,5-tetra-0-acety1- β -D-ribofuranose with 1,2,4-triazole at 160°C for 45 min in the presence of p-toluensulfonic acid as catalyst gave crystalline $\underline{4a}$ in 81% yield. 1-(2,3,4,6-tetra-0-acety1- β -D-glucopyranosy1)-1,2,4-triazole ($\underline{4c}$) was synthesized in 81% yield by refluxing a nitromethane solution of 1,2,4-triazole and α -acetobromoglucose in the presence of (CN)₂Hg⁹. Attempts to obtain $\underline{4c}$ by the fusion procedure using different acids as catalysts and heating at different temperatures, or by the silylation procedure $\underline{10}$ afforded much lower yields of nucleosidic material.

The glycosylation position was assigned, in both cases, as N-1 based on the different chemical shifts of the two triazole protons H-3 and H-5 (TABLE 1). The singlet appearing at lower field was assigned in each case to H-5¹¹. This assignation was confirmed by the differences in chemical shifts of H-3 and H-5 in (CD₃)₂SO and CDCl₃, since the chemical shift of the proton adjacent to the substituted nitrogen (H-5) in 1,2,4-triazoles is more sensitive to solvent changes than is that of H-3¹². Thus, the $\Delta \delta = \delta_{(CD_3)_2SO} - \delta_{CDCl_3}$ values for the lower field proton, H-5, were 0.5ppm for both $\frac{4a}{4a}$ and $\frac{4c}{4a}$. The $\Delta \delta$ values for the higher field proton, H-3 were 0.15 ppm for $\frac{4a}{4a}$ and 0.08 ppm for $\frac{4c}{4a}$.

The β anomeric configuration of $\underline{4c}$ was determined from the coupling constant $J_{1',2'}=9Hz$. The anomeric configuration

TABLE 1.	Chemical shift (5) and coupling constants (Hz)
	of glucosyl and ribosyl-1,2,4-triazoles 4-10.

					•	
Compd.	Solvent	H-1'	H - 3	н-5	CH ₂ X(5)	J _{1',2'}
<u>4a</u>	DMSO	6.39	8.27	8.88		4
<u>4a</u>	CDC1 ₃	6.09	8.12	8.38		
<u>4b</u>	DMSO	5.91	8.19	8.93		4
$\underline{4c}$	DMS0	6.20	8.18	8.96		9
<u>4c</u>	CDC1 ₃	5.72	8.10	8.46		
<u>5a</u>	DMSO	6.43	8.13		4.72	4
<u>5a</u>	CDC1 ₃	6.35	7.97		4.89	
<u>5c</u>	DMSO	6.33	8.07		4.79	8
<u>5c</u>	CDC1 ₃	5.90	7.94		4.93	
<u>6a</u>	CDC13	6.10	7.93		4.58	3
<u>6c</u>	CDC13	5.78	7.90		4.60	8
<u>7c</u>	CDC1 3	5.79	7.87		4.50	9
<u>8c</u>	CDC1 ₃	5.80	7.90		4.77	8
<u>9c</u> *	CDC13	6.37	7.87		4.18	9
10c **	CDC1 ₃	6.30	7.85		3.63	9

^{*&}amp; 2.98 (t,4,CH₂N), 3.60 (t,4,CH₂C1)

of $\underline{4a}$ could not be determined from the pmr spectrum, since $J_{1',2'}=3Hz$ could correspond to both a and β anomers 13 . So, compound $\underline{4a}$ was deacetylated by treatment with methanolic ammonia. Comparison of the physical properties of the resulting deprotected 1,2,4-triazole riboside $\underline{4b}$ with those of the known 1- (β -D-ribofuranosyl)-1,2,4-triazole 11 indicated that both compounds were identical.

5-Hydroxymethyl-1,2,4-triazole riboside <u>5a</u> and glucoside <u>5c</u> were obtained in 22 and 61% yield respectively by treatment of <u>4a</u> and <u>4c</u> with aqueous formaldehyde in dioxane at 105° and 115°C, respectively, in a sealed tube. Hydroxymethylation

^{**} δ 1.36 , 1.85 (2m, 4H, aziridine)

of the ribosyl-1,2,4-triazole <u>4a</u> gave also several partially deacetylated 5-hydroxymethyl-1,2,4-triazole ribosides. No 3-hydroxymethyl derivatives were detected.

The 5-substitution of the hydroxymethyl group was determined from the pmr spectra, which, in the aromatic protons zone only showed the higher field singlet corresponding to H-3. The small chemical shift differences of this singlet in $(CD_3)_2SO$ and $CDCl_3$ $\Delta \delta = 0.16$ for $\underline{5a}$ and $\Delta \delta = 0.13$ for $\underline{5c}$ was also in agreement with its assignation to H-3, according to the above mentioned criterion $\frac{12}{5c}$.

Reaction of 5a and 5c with triphenylphosphine and bromine gave the 5-bromomethyl analogues 6a, as an unstable syrup, and 6c as a solid. This, and the already observed lower stability of triacetylribofuranosyl-halomethyl-1,2,3-triazole in relation to the corresponding tetraacetylglucopyranosyl analogues, reccomended to only continue this study with the also cytostatic glucopyranosyl series 14. Reaction of 5-hydroxymethyl-1,2,3-triazole $\underline{5c}$ with triphenylphosphite and CCl_A afforded 5-chloromethyl derivative 8c in 79% yield. Transhalogenation reaction of 8c with sodium iodide gave iodomethyl derivative 7c in 83% yield. Unprotected alkylating halomethyl -1,2,3-triazole nucleosides are unstable³, while the corresponding acetylated derivatives are usually stable and show significant cytostatic activities 2,3. Thus, no attempts have been made to deacetylate the alkylating 1,2,4-triazole nucleosides of the present paper.

Nitrogen mustard and aziridine groups have been used as the alkylating residue in certain anticancer drugs 15 . They have been also incorporated into antitumor nucleosides. 5-[N,N-bis-(2-chloroethyl)] aminomethyl] uridine is active against leukemia 16 and $6-(1-aziridinyl)-9-(\beta-D-ribofuranosyl)-purine shows activity against adenocarcinoma <math>755^{17}$. In order to compare their cytostatic activities with those of the halomethyl-1,2,4-triazole glycosides synthesized above, having a halomethyl azole as a new benzylic type alkylating group,

we prepared other alkylating 1,2,4-triazole glycosides, having some of the classical alkylating groups such as nitrogen mustard and aziridine. Thus, 5-[N,N-bis-(2-chloroethyl) aminomethyl-1,2,4-triazole 9c was prepared in quantitative yield by treatment of 5-bromomethyl-1,2,4-triazole 6c with bis (2-chloroethyl)amine, freshly generated by reaction of the corresponding hydrochloride with aqueous KOH. The 5-aziridinomethyl derivative 10c was prepared in 50% yield by reaction of the 5-chloromethyl-1,2,4-triazole 8c with aziridine.

The cytostatic activity against HeLa cells of all the alkylating derivatives $\underline{6-10}$ reported in this paper has been evaluated 2,18 . The bromomethyl and iodomethyl-1,2,4-triazole

$$\begin{array}{c} & & & & & \\ & & & & \\ & & & & \\$$

derivatives $\underline{6c}$ and $\underline{7c}$ showed significant $ID_{50} = 2.5 \ \mu g/ml$ values. However, cytostatic activities of chloromethyl, N,N-bis- (2-chloroethyl)-aminomethyl and aziridinomethyl derivatives $\underline{6c}$, $\underline{9c}$ and $\underline{10c}$ respectively, were not significant ($ID_{50} = 25 \ \text{ug/ml}$).

EXPERIMENTAL

Melting points were determined on a Kofler hot-stage apparatus and are uncorrected. Proton nuclear magnetic resonance spectra were recorded with a varian EM-390 or a Perkin-Elmer R-12 spectrometer using Me₄Si as internal standard. Analytical thin-layer chromatography was performed on aluminum sheets

coated with a 0.2 mm layer of silica gel 60 F_{254} (Merck). Preparative layer chromatography was performed on 20 x 20 cm glass plates coated with a 2 mm layer of silica gel PF_{254} (Merck). Compounds were detected with a UV light (254 nm) or by spraying the plate with a ethanol-sulfuric acid (3:7) mix-ture and heating. Column chromatography was performed on glass columns filled with silica gel 60 70-230 mesh (Merck).

1-(2,3,5-Tri-0-acetyl-β-D-ribofuranosyl)-1,2,4-triazole (4a). A mixture of 1,2,3,5-tetra-0-acetyl-β-D-ribofuranose (10.2g,0.03 mol), 1,2,4-triazole (5.6 g,0.08 mol) and a catalytic amount of p-toluenesulfonic acid was heated at 160° C for 45 min. at reduced pressure. After cooling, the reaction mixture was dissolved in boiling ethanol, treated with charcoal and filtered. On cooling 4a crystallized (8.4g,81%), m.p. $110-111^{\circ}$ C.

<u>Anal.</u> Calcd. for $C_{13}^{H}_{17}^{N}_{3}^{O}_{7}$: C,47.70; H,5.23; N, 12.83. Found: C,47.45; H,5.42; N,13.20.

 $1-(\beta-D-Ribofuranosy1)-1,2,4-triazole$ (4b). Compound 4a (1 g, 0.003 mol) was treated with a saturated solution of methanolic ammonia. After standing at room temperature for

48 h. the solution was evaporated to dryness and the residue crystallized from EtOAc to give $\underline{4b}$ (0.54 g, 88%) m.p. 144-145. (lit 11 m.p. 143-145 $^{\circ}$ C).

1-(2,3,4,6-Tetra-0-acetyl-\$\beta\$-D-glucopyranosyl)-1,2,4-tria-zole. (4c). To a mixture of 2,3,4,6-tetra-0-acetyl-\$\overline{a}\cdot - \overline{a}\cdot - \overline{a

<u>Anal.</u> Calcd. for $C_{16}^{H}_{21}^{N}_{3}^{0}_{9}$: C, 48.11; H, 5.30; N, 10.52 Found: C, 48.30; H, 5.47; N, 10.71.

5-Hydroxymethyl-1-(2,3,5-tri-0-acetyl-β-D-ribofuranosyl)
-1,2,4-triazole (5a). A solution of 4a (5 g, 0.015 mol) in
dioxane (10 mL) and 35% aqueous formaldehyde (15 mL) was
heated in a sealed tube at 105°C for 16 h. On cooling, the
mixture was evaporated to dryness and the residue purified
by column chromatography, using EtOAc as eluant, to give 5a
(1.17 g, 22%) as a colorless syrup.

<u>Anal.</u> Calcd. for $C_{14}H_{19}N_3O_8$: C, 47.05; H, 5.35; N, 11.76 Found: C, 46.79; H, 5.78; N, 11.35.

5-Hydroxymethyl-1-(2,3,4,6-tetra-0-acetyl- β -D-glucopyra-nosyl)-1,2,4-triazole (5c). A solution of 4c (19.64g, 0.049 mol) in dioxane (50 mL) and 35% aqueous formaldehyde (133 mL) was heated in sealed tube at 115°C for 16.5h. On cooling, the

mixture was evaporated to dryness. The residue was suspended in EtOAc (25 mL) and filtered through silica gel 60 70-230 mesh (Merck), which was washed with more EtOAc. Filtrate and washing were evaporated to dryness and the residue was purified by column chromatography using EtOAc as eluant, to give <u>5c</u> (12.88 g, 61%) as a colorless syrup which on seeding crystalized from EtOAc-Petroleum ether. Seed crystals were obtained from pure syrupy <u>5c</u>, which spontaneously crystallized after standing at room temperature for one year m.p. 136°C.

Anal. Calcd. for $C_{17}^{H}_{23}^{N}_{3}^{O}_{10}$: C, 47.55; H, 5.39; N, 9.78. Found: C, 47.22; H, 5,73; N, 9.42.

5-Bromomethyl-1-(2,3,5-tri-0-acetyl-\$-D-ribofuranosyl)--1,2,4-triazole (6a). To a solution of 5a (2.17 g, 0.0066 mol) in anhydrous 1,2-dimethoxyethane (50 mL), tryphenylphosphite (3mL, 0.0099 mol) was added. The mixture was stirred at 0ºC for 30 min. Bromine (0.49 mL, 0.0099 mol) was added and the resulting mixture was stirred at room temperature for 1 h. Then, the solution was evaporated to dryness and the residue was purified by preparative tlc, using EtOAc - hexane (3:1) as solvent, to give 0.60 g of a syrup, the nmr spectrum of which showed that it was a mixture of 5a (major product) and some minor components. This syrup was not chromatographica-11y homogeneous and was purified repeatedly by the same system. Analytical tlc of the syrup after every chromatography showed the same by-products that have been eliminated in the previous preparative tlc. m/e 422 (M++1,1%), 420 $(M^{+}-1, 1\%)$.

5-Bromomethyl-1-(2,3,4,6-tetra-0-acetyl-β-D-glucopyra-nosyl)-1,2,4-triazole (6c). To a solution of 5c (2 g, 0.0046 mol) in anhydrous 1,2,-dimethoxyethane (30mL), triphenylphosphite (2.15 g, 0.0069 mol) was added. The mixture was stirred at 0° C in the absence of humidity for 30 min. Bromine (0.96 g, 0.006 mol) was added and the resulting mixture was stirred at

room temperature for 1 h. Then, the solution was concentrated in vacuo and the residue was purified by preparative tlc, using EtOAc - CHCl₃ (1:1) as eluant, to give pure <u>6c</u> (1.2 g, 52%), m.p. 137-138°C (EtOAc-Hexane).

Anal. Calcd. for C₁₇H₂₂Br N₃O₉: C, 41,46: H, 4.50; Br, 16.24; N, 8.53. Found: C, 41,42; H, 4,49; Br 16.08; N, 8.91.

5-Iodomethyl-1-(2,3,4,6-tetra-0-acetyl-\$\beta\$-D-glucopyranosyl)
-1,2,4-triazole (7c). A mixture of 8c (0.151 g, 0.34 m mol)
anhydrous acetone (4mL) and sodium iodide (0.0757 g, 0.5 m
mol) was heated to reflux for 5 min. The solid precipitated
(NaCl) was filtered and the filtrate evaporated to dryness.
The residue was dissolved in EtOAc and treated with an aqueous solution of sodium thiosulfate to decoloration. Then, the organic phase was washed twice with water, dried over sodium sulfate and evaporated to dryness to give 7c (0.152 g, 83%) as a light yellow solid m.p. 136-137°C (EtOAc-hexane).

Anal. Calcd. for C₁₇H₂₂ I N₃O₉: C, 37.86; H, 4.11; I, 23.52; N, 7.79. Found: C, 38.17; H, 3.99; I, 23.27; N, 7.82.

5-Chloromethyl-1- (2,3,4,6-tetra-0-acetyl-\$\beta\$-D-glucopyrano-syl-1,2,4-triazoles (8c). To a solution of 5c (0.85 g, 0.0021 mol) in anhydrous acetonitrile (27 mL) triphenylphosphine (1.07 g, 0.0039 mol) and CCl₄ (20mL) were added. The mixture was stirred at room temperature for 30 min and then evaporated to dryness. The residue was stirred for 30 min with cold anhydrous ether (50 mL) and the solid which precipitated was eliminated by filtration. The filtrate was evaporated to dryness and the residue was purified by preparative tlc , using chloroform as eluant, to give 8c (0.69 g, 78.5 %) m.p. 156-7°C (EtOAc-Hexane).

Anal. Calcd. for $C_{17}^{H}_{22}^{C1N}_{30}^{0}_{9}$: C, 45.60; H, 4.95; C1, 7.89; N, 9.38. Found: C, 45.99; H, 4.95; C1, 7.86; N, 9,67.

5-[Bis(2-chloroethyl) aminomethyl] -1-(2,3,4,6-tetra-0-acetyl-β-D-glucopyranosyl)-1,2,4-triazole (9c). A solution of $\underline{6c}$ (0. 56 g, 0.0011 mol) in dry acetone (10 mL) was treated with bis (2-chloroethyl) amine (0.5 g, 0.0036 mol) freshly liberated. This compound was obtained as a liquid by treatment of bis-(2-chloroethyl) amine hydrochloride with a cold aqueous KOH solution, extration of the mixture with ether, drying and evaporation of the organic phase. The acetone solution of $\underline{6c}$ and bis-(2-chloroethyl) amine was allowed to stand at room temperature for 48 h. Then, the solvent was removed and the residue was purified by preparative tlc, using chloroform as solvent to give pure $\underline{9c}$ (0.67 g, 97%) as a syrup.

Anal. Calcd. for $C_{21}^{H}_{30}^{C1}_{24}^{N}_{9}^{O}$: C, 45.59; H,5.46; C1, 12.78; N, 10.12. Found: C, 45.60; H, 5.61; C1,12.93; N, 9.79.

Compound $\underline{9c}$ was further characterized as the corresponding hydrochloride which crystallized from EtOAc, m.p. 203-204 $^{\circ}$ C.

Anal. Calcd for $C_{12}^{H}_{30}^{C1}_{2}^{N}_{4}^{0}_{9}$. HCl. C, 42.77; H, 5.30; Cl, 17.99; N, 9.50. Found: C, 43.02; H, 5.26; Cl, 17,63; N, 9.50.

5-[(1-Aziridino)methyl]-1-(2,3,4,6-tetra-0-acetyl-β-D-glucopyranosyl)-1,2,4-triazole (10c). To a solution of 8c (0.6 g, 0.0013 mol) in dry acetone (10 mL) aziridine (0.1 mL, 0.0019 mol) was added. The mixture was stirred at room temperature for 72 h. The solvent was evaporated and the residue was purified by preparative tlc, using EtOAc-Hexane (3:1) as eluant to yield 10c (0.33 g, 50%) as a light yellow syrup which crystallized on standing m.p. 144-146°C.

Anal. Calcd. for $C_{19}^{H}_{26}^{N}_{4}^{O}_{9}$: C, 50.21; H, 5.76; N, 12.33. Found: C, 49.88, H, 6.00; N, 12.05.

ACKNOWLEDGEMENT

The authors thank Mrs. Emilia Bayo for technical assistance.

REFERENCES

- 1. Paper nº 8 in the series "Alkylating Nucleosides". For previous paper in the series see ref. 2a.
- F.G. De las Heras, R. Alonso and G. Alonso. <u>J. Med. Chem.</u>
 496 (1979). 2a. F.G. De las Heras, R.M. Sánchez-Pérez and M.L. Aguado. <u>Eur. J. Med. Chem.</u> 16, 339 (1981).
- R. Alonso, M.J. Camarasa, G. Alonso and F.G. De las Heras.
 <u>Eur. J. Med. Chem.</u> 15, 105 (1980).
- 4. See also, W. Schörkhuber and E. Zbiral. <u>Chem. Ber. 114</u> 3165 (1981).
- M.T. García-López, R. Herranz and G. Alonso. <u>J. Med. Chem.</u>
 22, 807 (1979).
- M.T. García-López and R. Herranz. <u>Eur. J. Med. Chem. 15</u>, 551 (1980).
- J.T. Witkowski, R.K. Robins, R.W. Sidwell and L.N. Simon.
 <u>J. Med. Chem.</u> 15 1150 (1972).
- 8. For a comprehensive review on the Chemistry of 1,2,4triazoles see C. Temple "Triazoles 1,2,4" in "The Chemistry of Heterocyclic Compounds". A. Weissberger and E.C.
 Taylor (Eds) Interscience, New York, N.Y. 1981. Vol. 37.
- 9. N. Yamaoka, K. Aso and K. Matsuda. <u>J. Org. Chem.</u> <u>30</u>, 149 (1965).
- 10. H. Vorbrüggen and B. Bennua <u>Tetrahedron Letters</u>. 1339 (1978).
- 11. Joseph T. Witkowski and R.K. Robins. <u>J. Org. Chem.</u> <u>35</u>, 2635 (1970).

- 12. R. Jacquier, M.L. Roumestant and P. Viallefont. <u>Bull. Soc.</u> Chim. France 2630 (1967); ibid 2634 (1967).
- 13. L.B. Townsend in "Synthetic Procedures in Nucleic Acid Chemistry". Vol. 2, W.W. Zorbach and R.S. Tipson, Eds. Wiley Interscience, New York, N.Y. 1973, p. 331.
- 14. See reference 1 and 3
- 15. W.C.J. Ross, Hand. Exp. Pharmakol. 38, 33 (1975).
- 16. J. Farkaš and F. Šorm. <u>Collect. Czech. Chem. Commun.</u> 34 1696 (1969).
- 17. J.A. Montgomery, K. Hewson and C. Temple, <u>J. Med. Pharm.</u>

 <u>Chem.</u> 5, 15 (1962).
- 18. R.I. Geran, N.H. Greenberg, M.M. McDonald, A.M. Schumacher and B.J. Abbot. <u>Cancer Chemother</u>. <u>Rep.</u> Part 3, <u>3</u> 17 (1972).